BioPharmSignal logoBioPharmSignal

Biotech News

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PharmaCyte Biotech (PMCB)PharmaCyte BiotechCompany update

PMCB (PMCB) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is pmcb.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

TEVATeva Pharmaceutical Industries2026-06-10 16:03 EST

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

BMYBMYBristol-Myers Squibb Company2026-05-20 10:59 EST

Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

View all latest news

PharmaCyte Biotech

PharmaCyte Biotech was a biotechnology company focused on cell encapsulation and oncology before its restructuring and public-market decline. Its story centered on an experimental cancer-delivery platform.

Recent company news

PMCBPharmaCyte Biotech2025-11-25 14:15 EST

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PMCBPharmaCyte Biotech2025-09-02 13:20 EST

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

PMCBPharmaCyte Biotech2025-08-20 13:15 EST

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

PMCBPharmaCyte Biotech2025-08-18 13:15 EST

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

PMCBPharmaCyte Biotech2024-05-21 13:00 EST

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

Stock data

Close
0.59 USD
Market cap
8.06M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States